Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OVID – Ovid Therapeutics Inc.

Ovid Therapeutics Inc.
OVID
$1.03
Name : Ovid Therapeutics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $73,242,784.00
EPSttm : -0.54
finviz dynamic chart for OVID
Ovid Therapeutics Inc.
$1.03
7.63%
$0.073

Float Short %

2.71

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.07

EPS Last/This Y

-0.12

EPS This/Next Y

-0.06

Price

1.03

Target Price

3.4

Analyst Recom

1

Performance Q

259.26

Relative Volume

0.64

Beta

0.21

Ticker: OVID




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25OVID0.61980.000.00866
2025-07-28OVID0.5280.000.001037
2025-07-29OVID0.54030.000.001159
2025-07-30OVID0.50.000.001934
2025-07-31OVID0.50.000.001937
2025-08-01OVID0.50120.000.001940
2025-08-04OVID0.49640.000.002150
2025-08-05OVID0.49840.000.142276
2025-08-06OVID0.50020.000.142283
2025-08-07OVID0.51050.005.002276
2025-08-08OVID0.52040.000.002277
2025-08-11OVID0.55950.000.002287
2025-08-12OVID0.54110.000.002302
2025-08-13OVID0.9020.000.032303
2025-08-14OVID0.82160.000.002404
2025-08-15OVID0.96940.000.002821
2025-08-18OVID0.9330.000.043436
2025-08-19OVID0.94570.000.003631
2025-08-20OVID0.94860.000.003884
2025-08-21OVID0.95340.000.014136
2025-08-22OVID1.0350.000.004832
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25OVID0.62-225.0- -0.58
2025-07-28OVID0.53-225.0- -0.58
2025-07-29OVID0.54-225.0- -0.58
2025-07-30OVID0.50-225.0- -0.58
2025-07-31OVID0.50-225.0- -0.58
2025-08-01OVID0.50-225.0- -0.58
2025-08-04OVID0.50-225.0- -0.58
2025-08-05OVID0.50-225.0- -0.58
2025-08-06OVID0.51-225.0- -0.58
2025-08-07OVID0.51-225.0- -0.58
2025-08-08OVID0.51-225.0- -0.58
2025-08-11OVID0.56-225.0- -0.58
2025-08-12OVID0.55-225.0- -0.58
2025-08-13OVID0.86-225.0- -0.58
2025-08-14OVID0.84-225.0- -0.58
2025-08-15OVID0.96-225.0- -0.49
2025-08-18OVID0.92-222.9- -0.49
2025-08-19OVID0.94-222.9- -0.49
2025-08-20OVID0.95-222.9- -0.49
2025-08-21OVID0.95-222.9- -0.49
2025-08-22OVID1.0333.8- -0.49
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25OVID-0.02-18.291.75
2025-07-28OVID-0.02-31.951.75
2025-07-29OVID-0.02-31.951.75
2025-07-30OVID-0.08-31.951.75
2025-07-31OVID-0.08-31.951.75
2025-08-01OVID-0.08-31.951.75
2025-08-04OVID-0.08-31.681.75
2025-08-05OVID-0.08-31.681.75
2025-08-06OVID-0.08-31.681.75
2025-08-07OVID-0.08-31.681.75
2025-08-08OVID-0.08-31.681.75
2025-08-11OVID-0.08-31.681.75
2025-08-12OVID-0.08-31.682.71
2025-08-13OVID-0.08-31.682.71
2025-08-14OVID-0.08-31.682.71
2025-08-15OVID-0.08-31.682.71
2025-08-18OVID-0.08-37.852.71
2025-08-19OVID-0.08-37.852.71
2025-08-20OVID-0.08-37.852.71
2025-08-21OVID-0.08-37.852.71
2025-08-22OVID-0.08-37.852.71
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.06

Avg. EPS Est. Current Quarter

-0.13

Avg. EPS Est. Next Quarter

-0.13

Insider Transactions

-0.08

Institutional Transactions

-37.85

Beta

0.21

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

15

Growth Score

27

Sentiment Score

71

Actual DrawDown %

86.9

Max Drawdown 5-Year %

-96.7

Target Price

3.4

P/E

Forward P/E

PEG

P/S

11.01

P/B

1.31

P/Free Cash Flow

EPS

-0.54

Average EPS Est. Cur. Y​

-0.49

EPS Next Y. (Est.)

-0.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-574.02

Relative Volume

0.64

Return on Equity vs Sector %

-93.1

Return on Equity vs Industry %

-80.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.09

EBIT Estimation

Ovid Therapeutics Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 23
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
stock quote shares OVID – Ovid Therapeutics Inc. Stock Price stock today
news today OVID – Ovid Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OVID – Ovid Therapeutics Inc. yahoo finance google finance
stock history OVID – Ovid Therapeutics Inc. invest stock market
stock prices OVID premarket after hours
ticker OVID fair value insiders trading